Overview of Causality Assessment for Drug-Induced
Post# of 148109
(Total Views: 477)
Posted On: 10/30/2024 10:47:19 AM
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
Today's news:
"Dr. Palmer, either as the primary author or co-author with colleagues from the FDA, has published several guidelines concerning drug-induced liver injury among patients in clinical trials evaluating potential drugs to treat NASH and other liver diseases."
https://pmc.ncbi.nlm.nih.gov/articles/PMC8184702/
____
Today continues forward from Syneos news & Dr. Lataillade:
" we have a new and improved relationship with the FDA"
Today's news:
"Dr. Palmer, either as the primary author or co-author with colleagues from the FDA, has published several guidelines concerning drug-induced liver injury among patients in clinical trials evaluating potential drugs to treat NASH and other liver diseases."
https://pmc.ncbi.nlm.nih.gov/articles/PMC8184702/
____
Today continues forward from Syneos news & Dr. Lataillade:
" we have a new and improved relationship with the FDA"
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼